Real-World Experience of Risankizumab in Refractory Pediatric Inflammatory Bowel Disease.
This uncontrolled case series reports risankizumab use in 9 children with severe refractory inflammatory bowel disease after multiple biologic failures, with clinical remission in 5 patients, incomplete remission in 4, and no reported adverse events.
Open original publication →What the AI sees
This uncontrolled case series reports risankizumab use in 9 children with severe refractory inflammatory bowel disease after multiple biologic failures, with clinical remission in 5 patients, incomplete remission in 4, and no reported adverse events.
Research significance
The reported responses support the preliminary observation that IL-23 inhibition with risankizumab may benefit some children with multiply refractory IBD; inferring efficacy, durable safety, or relevance to pediatric cancer requires controlled studies and is not established by this record.
Source abstract
The incidence of pediatric inflammatory bowel disease (IBD) is rising globally. Anti-tumor necrosis factor agents remain the mainstay of treatment, but a significant number of patients experience treatment failure. This case-series presents real-world experience using risankizumab, an IL-23 inhibitor, in 9 children with severe-refractory IBD. Multiple biologics had failed in all patients before initiation. Response was assessed using symptoms, biomarkers, endoscopy, and imaging. Five patients achieved clinical remission, and 4 failed to achieve complete remission. Noninvasive monitoring tools, such as intestinal ultrasound, were used. No adverse events were reported. Risankizumab may be a promising option in refractory pediatric IBD.